Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.…
Caribou Biosciences (CRBU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Caribou Biosciences (NASDAQ: CRBU) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 97 employees.
The shares were at 0.2843 USD on 20 November 2026, down 86.4% over 52 weeks. Its 52-week range is 0.2819 USD to 2.490 USD, and it trades at the bottom of that range.
Its market capitalisation is 30.71M USD.
Caribou Biosciences reports return on equity of -121.2% and revenue down 26.9% year over year.
It holds more cash than debt, a net cash position of 68.46M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 4 March 2027.